Agilent Technologies (A) is back in focus after reporting strong Q2 2026 revenue growth, an earnings beat, and a raised full-year outlook, alongside plans for a China Innovation Center and the Biocare acquisition.

Agilent Technologies’ recent earnings beat and guidance raise appear to have shifted sentiment, with a 30 day share price return of 14.91% and a 1 year total shareholder return of 10.89%, even though the year to date share price return is still down 7.89%.

If this kind of earnings momentum has your attention, it could be a good moment to widen your watchlist and look for other healthcare and diagnostics plays using our 41 healthcare AI stocks

With Agilent Technologies now showing a 14.91% 30 day share price gain but still down 7.89% year to date, the key question is whether recent earnings strength is undervalued or whether the market is already pricing in future growth.

Most Popular Narrative: 21.1% Undervalued

With Agilent Technologies last closing at $127.06 against a narrative fair value of $161.00, the current pricing sits well below the valuation implied by widely followed assumptions that use a 7.94% discount rate.

Strategic investments in higher margin recurring revenue streams, including consumables, software, services, and digital platforms, are gaining traction, with CrossLab and services delivering consistent mid single digit growth and high customer satisfaction, indicating further margin expansion and greater earnings stability in future periods.

Want to see what is sitting behind that fair value for Agilent Technologies? The narrative leans heavily on compounding revenue, rising margins, and a richer earnings mix tied to recurring cash flows. Curious which growth and profitability assumptions are doing the heavy lifting in that model and how they connect to the current price gap? The full narrative lays out the numbers in detail.

Result: Fair Value of $161.00 (UNDERVALUED)

However, investors in Agilent Technologies still need to weigh tariff related cost pressures and potential funding constraints in academia and government, which could challenge this upbeat narrative.

Another View: What Agilent Technologies’ P/E Is Telling You

While the narrative fair value for Agilent Technologies points to undervaluation, its current P/E of 25.4x sits above an estimated fair ratio of 22.6x, even though it is lower than both peer and global Life Sciences averages. That mix of discount and premium raises a simple question: is the market already paying up for quality here, or still underestimating future delivery?

Next Steps

If this mix of optimism and open questions around Agilent Technologies has you thinking, now is a good time to look through the data yourself and test the assumptions that matter most to you. To see what is driving the more optimistic side of the story, take a closer look at the 4 key rewards.

Looking for more investment ideas beyond Agilent Technologies?

If Agilent Technologies has sharpened your interest, do not stop here. Use the Simply Wall Street Screener to uncover fresh opportunities other investors might overlook.

• Target potential mispricings by scanning for companies that look cheaper than their fundamentals suggest using the 45 high quality undervalued stocks.
• Strengthen portfolio resilience by focusing on businesses with solid finances and dependable balance sheets through the solid balance sheet and fundamentals stocks screener (48 results).
• Get ahead of the crowd by searching for lesser known companies with strong fundamentals using the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.